Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Two-part, Randomized, Double-blind, Placebo-controlled, First-In-Human, Phase I Study of the Safety, Tolerability, and Pharmacokinetics of SPR720 Following Administration of Single and Multiple Ascending Oral Doses in Healthy Volunteers

Trial Profile

A Two-part, Randomized, Double-blind, Placebo-controlled, First-In-Human, Phase I Study of the Safety, Tolerability, and Pharmacokinetics of SPR720 Following Administration of Single and Multiple Ascending Oral Doses in Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 15 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fobrepodacin (Primary)
  • Indications Nontuberculous mycobacterium infections; Tuberculosis
  • Focus Adverse reactions; First in man
  • Sponsors Spero Therapeutics
  • Most Recent Events

    • 07 Sep 2021 Results evaluating the safety, tolerability, and pharmacokinetics (PK) of SPR720/SPR719 in a single ascending dose (SAD) /multiple ascending dose (MAD) in healthy volunteers published in the Antimicrobial Agents and Chemotherapy
    • 25 Oct 2020 Results presented at the IDWeek 2020
    • 16 Oct 2020 According to a Spero Therapeutics media release, results from this study will be presented in a poster presentation at the Infectious Disease Society of America (IDSA) IDWeek 2020 taking place virtually from 21st to 25th Oct 2020.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top